Investor Presentation H1 2023

98 Investor presentation First six months of 2023 Innovative late-stage CVD pipeline provides opportunities to make a difference for many patients Focus areas Near-term Leverage broader CV indications to establish presence with Cardiologists and build an adequate PCP footprint for entry of stand-alone CVD product Medium-term Utilise leading scientific and commercial capabilities to launch first CVD stand-alone product Long-term Expand pipeline with differentiated MoAs through leading discovery and translational capabilities Examples of unmet needs in CVD pipeline Category Broader indications Stand-alone CVD Novo NordiskⓇ Study Current phase HFPEF Phase 3 Sema 2.4mg PAD Phase 3 Sema 1.0mg ATTR-CM Phase 2 NNC6019 Global unmet need (people) ~26m1 ~200m No consensus (estimated 0.1- 2.8 cases per 10,000 in EU) Potential differentiators 1st in class indication² First and only for T2D Reverse disease pathology Potential launch year 2024 2024/25 2028 1HFPEF and BMI>27 2Specifically for a functional outcomes trial in an obese patient population PCP: Primary Care Physician; CV(D): Cardiovascular Disease; MOA: Mode of Action; HFPEF: Heart failure with preserved ejection fraction; PAD: Peripheral arterial disease; ATTR-CM: Transthyretin Amyloid Cardiomyopathy; T2D: Type 2 Diabetes Sources: HFPEF: Groenewegen A et al. Eur J Heart Fail 2020;22:1342-13561; Gurwitz JH et al. Am J Med 2013;126:393-400; Haass M et al. Circulation 2011;4:324-331; Kitzman DW, et al. J Am Coll Cardiol 2016;68:200-203; PAD: Shu J, Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts, 22 May 2018; ATTR-CM: Orphan Maintenance Assessment Report for tafamidis, EMA, 17 February 2020

View entire presentation